Optomed Oyj

Optomed Plc reported a decline in financial performance for Q3 2024, with revenue decreasing by 26.3% compared to Q3 2023. The Devices segment saw a significant drop of 55.5% in revenue, mainly due to the absence of large orders that had been present in the previous year. The Software segment experienced a smaller decline of 4.0%. The company's gross margin fell to 54.4% from 67.4%, influenced by an inventory revaluation. EBITDA was reported at EUR -814 thousand, a sharp decline from the previous year. Optomed's net debt increased by 70.6%, reaching EUR -8,343 thousand. Despite these challenges, the company highlighted progress in the oculomics field and the commercialization of Aurora AEYE, with new market opportunities and strategic partnerships. Optomed expects a decrease in full-year 2024 revenue compared to 2023. The company maintains a strong cash position of EUR 11 million. The Annual General Meeting elected the Board of Directors and confirmed no dividend payout for 2023. Optomed continues to focus on innovation in healthcare diagnostics and strategic partnerships.

Optomed Plc announced on September 30, 2024, that it has received a notification from Danske Bank A/S regarding a change in holdings. As of September 26, 2024, Danske Bank A/S holds 5.08% of Optomed's total shares and voting rights, amounting to 997,607 shares out of the company's 19,630,397 registered shares. This disclosure is made under Chapter 9, Section 10 of the Finnish Securities Markets Act. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software for diagnosing eye diseases, with operations in over 60 countries. Further inquiries can be directed to Sakari Knuutti, CFO of Optomed.

Optomed Plc has issued a profit warning, revising its full-year 2024 revenue outlook to a decrease from 2023. This change is due to postponed key deliveries in the Software Segment and slower-than-expected sales in the Devices Segment. Despite anticipated strong revenue growth in the US and China, the overall revenue is expected to decline. The Q3-2023 period had been positively impacted by a significant delivery worth approximately EUR 800,000 to Valencia, Spain. Sales of the Optomed Aurora AEYE have begun and received positive feedback, but its recurring revenue service will not significantly affect the 2024 revenue outlook. The previous outlook, announced in February 2024, had anticipated revenue growth for the year. Optomed will publish its Interim Report for January-September 2024 on 7 November 2024. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and screening software, with operations in Finland, the US, and China, and sales in over 60 countries.

On 11 September 2024, Optomed Plc announced the composition of its Nomination Board based on the shareholder register as of 2 September 2024. The shareholders represented on the Nomination Board are OP-Rahastoyhtiö Oy (OP funds), SP-Rahastoyhtiö Oy (SP Funds), and Danske Invest Rahastoyhtiö Oy (Danske Funds). Petri Salonen, Chairman of Optomed’s Board of Directors, will serve as the Nomination Board's expert member. The Nomination Board, consisting of representatives from Optomed's three largest shareholders and the Chairman of the Board, is tasked with preparing proposals on the composition and remuneration of the Board of Directors for the next Annual General Meeting. The proposals are to be submitted by 31 January 2025. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and eye-screening devices, with operations in over 60 countries. Further inquiries can be directed to Petri Salonen at petri.salonen@optomed.com.

Optomed Plc announced a manager's transaction involving Markku Myllylä, a senior manager. The transaction, which took place on August 9, 2024, involved the disposal of financial instruments linked to a share or a debt instrument, specifically Optomed Oyj's 2018 C stock options. The transaction volume was 60,000 units at a unit price of 1.2756 EUR, resulting in a volume-weighted average price of 1.2756 EUR. This notification is classified as an initial notification with the reference number 74101/4/4.